BostonGene to Participate in the 114th Annual Meeting of the United States and Canadian Academy of Pathology
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced that two abstracts have been accepted for poster presentation at the United States and Canadian Academy of Pathology (USCAP) 114th Annual Meeting. The event, held from March 22-27 at the Boston Convention and Exhibition Center in Boston, MA, is the premier gathering of pathology and laboratory medicine professionals, showcasing cutting-edge research, diagnostic advancements and emerging technologies to advance patient care and precision medicine.
Details of the poster presentations are below:
Title: Profiling the Intratumor Microbiome in Prostate Cancer (PC) Reveals Consistent Signatures Across Different Metastatic Sites and Correlates with the Tumor Microenvironment (TME)
Abstract: 147
Time and Location: Monday, March 24 | 1:00 PM - 4:30 PM
Presenter: Eda Nur Kozan, MD, Weill Cornell Medicine
A recent pilot study uncovered associations between bacterial profiles, the tumor microenvironment (TME), and histology in metastatic castration-resistance prostate cancer (mCRPC). Using BostonGene’s machine learning-based tools, RNA sequencing data were analyzed to characterize each sample’s microbiota and TME. Distinct bacterial patterns were present across prostate cancer subtypes and TME classifications, with strong correlations observed among the microbiomes of metastatic sites.
Research done in collaboration with Weill Cornell Medicine
Title: Reconstruction of the Glioblastoma (GBM) Tumor Immune Microenvironment (TIME) Reveals Unique Subtypes with Potential Prognostic Significance
Abstract: 248
Time and Location: Tuesday, March 25 | 9:30 AM - 12:30 PM
Presenter: Eda Nur Kozan, MD, Weill Cornell Medicine
This collaborative study identified novel GBM TIME subtypes associated with prognosis. Unsupervised clustering was applied to transcriptomic data from a meta-cohort of 867 publicly available samples and 30 BostonGene Tumor PortraitTM test samples to define five TIME subtypes linked with overall survival. This study illustrates the power of molecular profiling for identifying prognostic biomarkers in GBM.
Research done in collaboration with Weill Cornell Medicine
For more information or to schedule a meeting with BostonGene during the event, please contact Hannah Oman at [email protected].
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
